Amgen Lung Cancer Drug Combo Cuts Death Risk by 58%
A new drug combination from Amgen and AstraZeneca helps patients with aggressive lung cancer live longer.
Patients fighting aggressive lung cancer have new hope today. A fresh clinical trial shows a strong leap forward for people facing this tough disease.
Biotech giant Amgen paired its drug with a treatment from AstraZeneca. This combination cut the risk of death by 58 percent compared to standard care. Patients gained critical months of life.
This type of cancer spreads quickly and resists most treatments. Amgen's drug trains the immune system to hunt down tumor cells. When doctors add AstraZeneca's medicine, the body attacks the cancer even harder.
This breakthrough gives families precious time together. It also shows how biotech partnerships can solve hard medical problems. Strong medical wins like this push the whole healthcare sector forward.
Source: CNBC
More from Biotech
